Warfarin Interaction Assessment and Management

Introduction to Warfarin Interactions

The American College of Cardiology recommends that Orencia (abatacept) can be used with warfarin without requiring intensified INR monitoring or prophylactic warfarin dose reduction, as it does not undergo hepatic metabolism via CYP450 enzymes and does not affect warfarin's pharmacokinetics 1
The American Heart Association suggests that abatacept does not require special precautions beyond standard monitoring when used with warfarin, unlike other immunosuppressants such as leflunomide 2

The American College of Cardiology recommends continuing routine INR monitoring at the frequency appropriate for the patient's warfarin stability, typically every 4 weeks for stable patients 3
The American College of Cardiology suggests maintaining a target INR of 2.0-3.0 for most indications, recognizing that bleeding can occur even within therapeutic range 4, 3

The American Heart Association warns that fluoroquinolones, macrolides, and trimethoprim-sulfamethoxazole significantly increase INR through CYP2C9 inhibition or gut flora alteration, and recommends increasing INR monitoring to weekly when initiating these antibiotics 1, 7
The American College of Cardiology recommends considering preemptive warfarin dose reduction of 20-30% when starting interacting antibiotics 7

The American College of Cardiology states that elderly patients (≥75 years) require approximately 1 mg/day less warfarin than younger patients to maintain comparable INR, and have significantly higher risk of intracranial and gastrointestinal bleeding even at therapeutic INR levels 4, 3
The American Heart Association suggests that age >65 years, history of stroke or GI bleeding, renal insufficiency, and anemia are additive risk factors for bleeding, and patients with 2-3 risk factors have substantially higher bleeding incidence than those with none 4

The American College of Cardiology recommends holding 1-2 warfarin doses and resuming at lower dose when INR approaches therapeutic range for INR 3.0-9.0 without bleeding, and administering vitamin K1 3-5 mg orally for INR >9.0 without bleeding 4, 7
The American College of Cardiology suggests giving vitamin K1 10 mg by slow IV infusion plus fresh frozen plasma or prothrombin complex concentrate for serious bleeding or major overdose, and repeating vitamin K1 every 12 hours as needed based on INR response 4